The FDA has approved Leqembi (Lecanemab) for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. Approval followed a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease. In studies reviewed by the FDA, Leqembi appeared to slow declines in memory and thinking by about 27% after 18 months of treatment. Medicare coverage is significant because the drug is projected to cost about $26,500 per year.
The FDA’s acting director of the Office of Neuroscience in its Center for Drug Evaluation and Research said:
Today’s action is the first verification that a drug targeting the underlying disease process of Alzheimer’s disease has shown clinical benefit in this devastating disease. This confirmatory study verified that it is a safe and effective treatment for patients with Alzheimer’s disease.
Other approved treatments include:
Recently, my dad died. While I was driving back from being sworn in as his…
In Georgia, an individual has legal capacity to make a Will "when the testator has…
Last updated 2/28/2025 The Georgia Power of Attorney Act was enacted in 2017 (HB 221)…
In North Carolina Department of Revenue v. The Kimberley Rice Kaestner 1992 Family Trust, the…
Medicaid is critical for individuals with special needs. It pays for things no one else…
Since 1980, Medicare pays after another responsible entity pays certain health care claims for Medicare…